Eric Halioua, President & CEO of PDC*line Pharma will be a panelist in a round table on Oncology Advanced Therapeutics & Diagnostics at the 19th Biotech in Europe Forum. A Sachs Associates event...

Forum

Liège, Belgium, and Grenoble, France, September 9, 2019 – PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces...

Press releases

Our President & CEO Eric Halioua will present the unique mechanism of action of our proprietary Plasmacytoid Dendritic Cell line (PDC*line) at the "Science for Health 2019"! Come join the Cell Therapy...

Events

Have a look to the great video made by MATWIN for its 10 years anniversary serving innovation in oncology ! The video includes a contribution of PDC*line Pharma with an interview of our CEO Eric...

In the press

PDC*line Pharma is - for the first time – an active partner of the Forum BIOTechno Auvergne-Rhône-Alpes 2019. The event will take place June, 11th at the Centre de Congrès du World Trade Center...

Forum

Please read our recent publication in the June 2019 edition of Nature Biopharma Dealmakers! The article highlights the key competitive advantages of our technology PDC*vac: a highly potent, versatile,...

In the press

The PDC*line Pharma management team will be present in full force to 2019 BIO International Convention in Philadelphia from June 3rd to June 6th! 👉 Contact us through the One-on-One Partnering™ or...

Events

Available now for replay, PDC*line Pharma 's CEO Eric Halioua presentation at the ARM's Meeting Cell & Gene Meeting on the Mediterranean 2019 (Barcelona). Learn more about the unique mechanism of...

Forum

PDC*line Pharma CEO Eric Halioua and COO Laurent Levy will be present at the Bio€quity Europe 2019 conference in Barcelona May 20-21! Our CEO will present the company May 21st at 10:30am 👉 Don’t...

Events

Liège, Belgium, and Grenoble, France, May 7, 2019 - PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, announces today...

Press releases